ACA
ABBV icon

Aspire Capital Advisors’s AbbVie ABBV Stock Holding History

Aspire Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$218K Sell
1,004
-23
-2% -$5.1K 0.05% 113
2025
Q4 		$235K Buy
+1,027
New +$234K 0.06% 105

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aspire Capital Advisors's ABBV Position: Q1 2026 in Review

Aspire Capital Advisors reduced its AbbVie (ABBV) stake by 2.2% in Q1 2026, selling an estimated $5.1K and leaving 1,004 shares worth $218K. The position accounts for 0.05% of the portfolio, ranked #113.

Aspire Capital Advisors first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. The position peaked at $235K in Q4 2025. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Aspire Capital Advisors held 1,004 shares of AbbVie worth $218K as of Q1 2026.
  • Aspire Capital Advisors sold 23 AbbVie shares in Q1 2026, an estimated $5.1K.
  • AbbVie made up 0.05% of Aspire Capital Advisors's portfolio in Q1 2026, its #113 holding.
  • Aspire Capital Advisors first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
  • Aspire Capital Advisors's AbbVie position peaked at $235K in Q4 2025.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Aspire Capital Advisors's 13F filing for Q1 2026, filed 22 Apr 2026.